TABLE 5.
ORs and 95% CIs of BT according to baseline characteristics among 67 patients treated with ETV for 3 years
| Characteristic | Non-BT (n = 56)a | BT (n = 11)a | P for difference | Contrast | OR | 95% CI |
|---|---|---|---|---|---|---|
| Age (mean) | 45.4 ± 8.1 | 45.4 ± 9.4 | 0.932 | 1-yr increase | 1 | 0.92-1.08 |
| Male (%) | 71.4 | 81.8 | 0.481 | Male vs. female | 1.8 | 0.35-9.26 |
| ALT (mean) | 115.9 ± 105.6 | 126.2 ± 127.3 | 0.832 | 1-U increase | 1 | 0.99-1.00 |
| HBeAg (%) | 66.1 | 81.8 | 0.307 | Positive vs. negative | 2.31 | 0.45-11.78 |
| HBV-DNA | ||||||
| Level (mean) | 6.8 ± 1.6 | 7.1 ± 0.8 | 0.959 | 1-U increase | 1.16 | 0.72-1.89 |
| 2-log-unit reduction at 1 yr (%) | 98.2 | 63.6 | <0.001 | With vs. without | 0.03 | 0.00-0.33 |
| DNA <2.6 at 1 yr (%) | 58.9 | 0.0 | <0.001 | With vs. without | NAb | |
| LVD refractory (%) | 32.1 | 100.0 | <0.001 | With vs. without | NA | |
| Amino acid substitutions at baseline | ||||||
| V80 (%) | 3.6 | 18.2 | 0.063 | With vs. without | 6 | 0.74-48.17 |
| I80 (%) | 17.9 | 36.4 | 0.171 | With vs. without | 2.63 | 0.64-10.72 |
| L173 (%) | 3.6 | 18.2 | 0.063 | With vs. without | 6 | 0.75-48.18 |
| M180 (%) | 28.6 | 100.0 | <0.001 | With vs. without | NA | |
| V204 (%) | 19.6 | 90.9 | <0.001 | With vs. without | 10.91 | 4.72-354.28 |
| I204 (%) | 23.2 | 36.4 | 0.363 | With vs. without | 1.89 | 0.48-7.49 |
| Amino acid substitutions during ETV therapy (3 yr) | ||||||
| SCGA/ILFM184 (%) | 1.8 | 72.7 | <0.001 | With vs. without | 96.25 | 9.38-987.41 |
| G202 (%) | 1.8 | 63.6 | <0.001 | With vs. without | 146.67 | 13.55-1,587.24 |
a
Values are means ± standard deviations.
b
NA, not applicable.